ISRCTN13083896
Completed
Phase 3
A phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with cystic fibrosis at 3-6 years of age in parallel with the North American SHIP clinical trial
Cystic Fibrosis Foundation Therapeutics0 sites120 target enrollmentNovember 5, 2015
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Cystic fibrosis
- Sponsor
- Cystic Fibrosis Foundation Therapeutics
- Enrollment
- 120
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
2022 Results article in https://doi.org/10.1016/S2213-2600(21)00546-4 (added 13/05/2022)
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Diagnosis of CF as evidenced by one or more clinical features consistent with the CF phenotype or positive CF newborn screen AND one or more of the following criteria:
- •1\.1\. A documented sweat chloride \= 60 mEq/L by quantitative pilocarpine iontophoresis (QPIT)
- •1\.2\. A documented genotype with two disease\-causing mutations in the CFTR gene
- •2\. Informed consent by parent or legal guardian
- •3\. Age \= 36 months and \=72 months at screening visit
- •4\. Ability to comply with medication use, study visits and study procedures as judged by the site investigator
- •5\. Ability to cooperate with chest CT at the enrolment visit as determined by the lung function technician
Exclusion Criteria
- •1\. Chest CT within 8 months prior to the Screening visit
- •2\. Acute intercurrent respiratory infection, defined as an increase in cough, wheezing, or respiratory rate with onset within 3 weeks preceding screening or enrolment visit
- •3\. Acute wheezing at screening or enrolment visit
- •4\. Oxygen saturation \< 95% (\<90% in centres located above 4000 feet elevation) at screening or enrolment visit
- •5\. Other major organ dysfunction, excluding pancreatic dysfunction
- •6\. Physical findings that would compromise the safety of the participant or the quality of the study data as determined by site investigator
- •7\. Investigational drug use within 30 days prior to screening or enrolment visit
- •8\. Treatment with inhaled HS at any concentration within 30 days prior to screening or enrolment visit
- •9\. Start of any additional inhaled saline solution at any concentration, or other hydrating agent such as mannitol or mucolytic drug such as dornase alpha within 30 days prior or following the Screening or Enrolment visit
- •10\. Chronic lung disease not related to CF
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
MS-STAT2 : Multiple Sclerosis - Simvastatin Trial 2Multiple sclerosisNervous System DiseasesDemyelinating diseases of the central nervous systemISRCTN82598726niversity College London964
Completed
Phase 3
IgNiTE: Immunoglobulin in the treatment of encephalitisEncephalitisNervous System DiseasesEncephalitis, myelitis and encephalomyelitis, unspecifiedISRCTN15791925niversity of Oxford18
Completed
Phase 3
A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patientsBreast cancerCancerISRCTN48254013Imperial College of Science and Technology (UK)2,639
Completed
Phase 3
A multicentre, phase III, randomised, double-blind, placebo-controlled trial of pravastatin added to first-line chemotherapy in patients with small cell lung cancerISRCTN56306957niversity College London (UK)860
Completed
Phase 2
Fulvestrant and vandetanib in advanced aromatase inhibitor resistant breast cancerMetastatic breast cancerCancerISRCTN13663157Velindre NHS Trust165